Oxandrolone Tablets 5 mg
OXA-PHARM (Oxandrolone Tablets 5 mg), Oral tablets, contains Oxandrolone 5 mg.
Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of this class of drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are therefore similar to those of male sex hormones with the possibility of causing serious disturbances of growth and sexual development if given to young children. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes. During exogenous administration of anabolic androgens, endogenous testosterone release is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).Anabolic steroids have been reported to increase low-density lipoproteins and decrease high-density lipoproteins. These levels revert to normal on discontinuation of treatment. Nitrogen balance is improved by anabolic agents only when there is sufficient intake of calories and protein. Whether this positive nitrogen balance is of primary benefit in the utilization of protein-building dietary substances has not been established.
Oxandrolone is rapidly absorbed from the gastrointestinal tract, and extensively bound to plasma proteins. It is excreted mainly in the urine as unchanged Oxandrolone and some metabolites, with an elimination half-life of about 9 to 10 hours. A small amount is excreted in the faeces
Indications and Usage
Oxandrolone tablets are indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis.
Dosage and Administration
Oxandrolone has anabolic and androgenic properties and is given as adjunctive therapy to promote weight gain in oral doses of 2.5 to 20 mg daily in 2 to 4 divided doses. Treatment is usually given as a course of 2 to 4 weeks, which may be repeated intermittently as required. Elderly patients may be more susceptible to the adverse effects of Oxandrolone, and a dose of up to 5 mg twice daily is recommended.
Testosterone and other androgens may give rise to adverse effects related to their androgenic or anabolic activities. These include increased retention of sodium and water, oedema, hypercalcaemia, and impaired glucose tolerance. Other effects include increased lowdensity- lipoprotein cholesterol, decreased high-density- lipoprotein cholesterol, increased haematocrit, and suppression of clotting factors. Androgens may cause headache, depression, and gastrointestinal bleeding. It has been suggested that androgens may induce sleep apnoea in susceptible patients. Abnormal liver function tests may occur and there have been reports of liver toxicity including jaundice and cholestatic hepatitis. There have also been reports of peliosis hepatis and hepatic tumours in patients who have received high doses over prolonged periods. These adverse hepatic effects have occurred primarily with the 17α-alkylated derivatives (e.g. methyltestosterone, stanozolol). In men, large doses suppress spermatogenesis and cause testicular atrophy. Epididymitis and bladder irritability can occur. Priapism is a sign of excessive dosage and may occur especially in elderly males. Gynaecomastia may occur. Androgens may cause prostatic hyperplasia and accelerate the growth of malignant neoplasms of the prostate. Continued use produces symptoms of virilism, such as hirsutism or male-pattern baldness, deepening of the voice, atrophy of the breasts and endometrial tissue, oily skin, acne, and hypertrophy of the clitoris. Virilisation may not be reversible, even after stopping therapy. Large and repeated doses in early puberty may cause closure of the epiphyses and stop linear growth. Children may experience symptoms of virilisation: in boys there may be precocious sexual development with phallic enlargement and increased frequency of erection, and in girls, clitoral enlargement. Gynaecomastia may also occur in boys. Masculinisation of the external genitalia of the female fetus may occur if androgens are given during pregnancy. After transdermal application of testosterone, skin reactions may include irritation, erythema, allergic contact dermatitis, and sometimes burn-like lesions. Skin reactions are more common with patches that contain permeation enhancers. The anabolic steroids, because they generally retain some androgenic activity, share the adverse effects of the androgens described above, but their virilising effects, especially in women, are usually less. There have been reports of adverse psychiatric effects in athletes taking large doses to try and improve performance.
No symptoms or signs associated with overdosage have been reported. It is possible that sodium and water retention may occur..
Store in cool dry place below 30°C. Protect from light.
A carton containing 5 blisters of 20 tablets each along with pack insert.
México Juárez Farmacéuticos S.A.